SCHEDULE: Vanguard Divests Entire Rani Therapeutics Stake

The Vanguard Group has reported a 0% beneficial ownership in Rani Therapeutics Holdings Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to Schedule 13G for Rani Therapeutics Holdings Inc. (CUSIP: 753018100).
• The filing indicates that The Vanguard Group now beneficially owns 0 shares of Common Stock, representing 0% of the class.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis), and The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over those securities.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative development for Rani Therapeutics. While the reason is an internal Vanguard realignment, the complete removal of a major institutional investor's stake can create negative market sentiment and reduce institutional support for the stock.

Negatives

• The Vanguard Group, a major institutional investor, no longer holds any beneficial ownership in Rani Therapeutics Holdings Inc.
• The complete divestment by a prominent asset manager could signal a lack of confidence or a change in investment strategy regarding Rani Therapeutics, even if attributed to internal restructuring.

Risks

• Potential negative market perception due to a significant institutional investor reducing its stake to zero.
• Reduced institutional support and demand for Rani Therapeutics' stock.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Rani Therapeutics Holdings Inc.'s future performance or operations.

Industry Context

StockSavvy.ai notes that the complete divestment by a major institutional investor like The Vanguard Group, even if due to internal restructuring, can sometimes be interpreted by the market as a negative signal for the underlying company, Rani Therapeutics Holdings Inc. While Vanguard states the change is due to internal realignment and disaggregated reporting, investors often monitor institutional ownership changes closely as indicators of sentiment or fundamental shifts.

Stakeholder Impact

• Shareholders: Existing shareholders might react negatively to the news of a major institutional investor divesting its entire stake, potentially leading to downward pressure on the stock price due to perceived loss of institutional confidence or reduced demand.

Key Dates

Recommendation

The complete divestment by a major institutional investor like The Vanguard Group, even if due to internal restructuring, removes a significant holder from the shareholder base. This could signal a lack of long-term conviction from a prominent fund manager, potentially leading to negative market sentiment and reduced institutional demand for the stock. Investors might consider selling to avoid potential downward pressure or to reallocate capital to companies with stronger institutional backing.

Keywords

Rani Therapeutics Holdings Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Divestment, Common Stock, SEC Filing